Chloe James MD, PhD

Course and current status

I did my medical studies in Paris V (Necker) and moved to Bordeaux for my internship. I chose to specialize in clinical haematology. Between 2003 and 2010, I interupted my medical training to perform researcj in Villejuif, with Dr William Vainchenker, in Bordeaux with Pr De Verneuil, and then moved for a post doc in Melbourne (Dr Benjamin Kile). I came back in Bordeaux in 2010, in the laboratory of haematology of the University Hospital of Bordeaux. 

I set up my own Atip-Avenir group in the laboratory of Pr Thierry Couffinhal. I am now Assistant Professor and since february 2016, I'm the head of the laboratory of Haematology of of the University Hospital of Bordeaux. 

Scientific summary

During these last 10 years, I have been working in haematology and haemostasis. I was a shared first author in the discovery of the JAK2V617F mutation in myeloproliferative neoplasms (James et al, Nature, 2005), which is the most frequent molecular abnormality found in this family of acquired haematological malignancies. This discovery did not only lead to a better understanding of these diseases, but more practically, to a much easier diagnosis flow chart for patients as they now only need a blood test (James et al, Leukemia, 2006). It also led to the development of JAK2 inhibitors, which are now approved for patients and improve their quality of life and even life expectancy. At this same period, I also contributed to the discovery of TET2 mutations in these same malignancies (Delhommeau et al, NEJM, 2009), which shed light on the role of epigenetics in myeloid malignancies.

Because I wanted to specialize in haemostasis, I went to Melbourne, Australia, where I worked in the field of platelet production in the prestigious group of Prof. Benjamin Kile. Jointly we deciphered the role of intrinsic apoptosis in platelet production (Josefsson et al, J Exp Med, 2011). These results have important applications in the clinic, as drugs targeting intrinsic apoptosis are developed in order to target cancer cells.

These last 4 years, I went back half time to the clinic (University Hospital in Bordeaux, department of Haemostasis) and half time in INSERM1034 where I set up my own ATIP-AVENIR group. We are using the model of JAK2V617F myeloproliferative neoplasms, where unexplained thrombosis frequently occurs, to demonstrate that endothelial cells are active players in the pathogenesis of thrombosis. 

Image d’exemple